UBS Group’s Zivo Bioscience, Inc. Common Stock ZIVO Stock Holding History

UBS Group’s Portfolio ZIVO Stock Details ZIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-142	Closed	-$2.62K	–	10099
2023 Q1	$2.62K	Sell	142 -153	-52%	-$2.84K	﹤0.01%	8477
2022 Q4	$4.42K	Buy	+295	New	+$5.15K	﹤0.01%	9339
2022 Q2	–	Sell	-523	Closed	-$12K	–	11291
2022 Q1	$12K	Sell	523 -240	-31%	-$4.78K	﹤0.01%	8229
2021 Q4	$13K	Buy	763 +411	+117%	+$8.6K	﹤0.01%	8490
2021 Q3	$10K	Buy	+352	New	+$7.7K	﹤0.01%	8036

Other funds holding ZIVO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

VCA

Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group's ZIVO Position: Q2 2023 in Review

UBS Group sold out of Zivo Bioscience, Inc. Common Stock (ZIVO) in Q2 2023, closing a stake of 142 shares — an estimated $2.62K sold.

UBS Group first reported a position in ZIVO in Q3 2021 and held it in 5 quarters. The position peaked at $13K in Q4 2021. 12 funds tracked by Wall St. Rank hold ZIVO as of Q2 2023.

UBS Group reported no remaining Zivo Bioscience, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 142 Zivo Bioscience, Inc. Common Stock shares in Q2 2023, an estimated $2.62K.
UBS Group first reported a position in Zivo Bioscience, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
UBS Group's Zivo Bioscience, Inc. Common Stock position peaked at $13K in Q4 2021.
12 funds tracked by Wall St. Rank held Zivo Bioscience, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.